Evgen Pharma PLC Patent Grant in the United States (8644W)
February 14 2017 - 7:30AM
UK Regulatory
TIDMEVG
RNS Number : 8644W
Evgen Pharma PLC
14 February 2017
For immediate release 14 February 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Patent Grant in the United States
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that the United States Patent
and Trademark Office has granted a patent that significantly
broadens and extends the Company's intellectual property around its
lead product, SFX-01.
SFX-01 is a synthetic version of the naturally occurring
compound sulforaphane, which has been stabilised in an
alpha-cyclodextrin lattice. The current patent protection is
composition of matter and runs until 2028. This new patent, granted
today under number US9,567,405 and entitled Method of Synthesizing
Sulforaphane, covers the manufacturing process and runs until
2033.
The exclusive worldwide rights to the patent are held by Evgen
Pharma under the terms of a licence agreement with PharmAgra Labs
Inc., the US laboratory that invented SFX-01.
Evgen Pharma is currently conducting two Phase II trials of
SFX-01, one in advanced breast cancer and one in a type of stroke
called subarachnoid haemorrhage.
Dr Stephen Franklin, CEO of Evgen Pharma, commented: "This
patent grant extends our intellectual property protection in the
world's largest pharmaceutical market and is the first of a
potentially broad geographical spread of patents that are pending
in Europe, Japan, India, China, Canada, Brazil and Australia".
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
www.evgen.com
Buchanan +44 (0) 20 7466
Mark Court, Sophie Cowles, Stephanie Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou
(Corporate Finance) +44 (0) 20 3861
John Howes and Rob Rees (Corporate Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
registered office at the Liverpool Science Park and is a virtual
tenant at the Biohub at Alderley Park, Cheshire, UK. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information please visit: www.evgen.com
For a recent analyst research note on Evgen Pharma, please
visit:
http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEADALFFNXEFF
(END) Dow Jones Newswires
February 14, 2017 08:30 ET (13:30 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024